Therapy Areas: Oncology
Rafael Holdings, reports financial results for fourth quarter and fiscal year ended 31 July 2020
30 October 2020 -

Rafael Holdings, Inc, (NYSE: RFL), a company focused on the development of novel cancer therapies, has reported its financial results for the fourth quarter and fiscal year ended 31 July 2020, it was reported on Thursday.

The company reported revenue of USD4.9m and a loss per share of USD0.66 for the fiscal year ended 31 July 2020.

During the fourth quarter of 2020, the company reported revenue of USD1.2m and loss per share of USD0.34.

Howard Jonas, chairman and CEO of Rafael Holdings remarked, 'Rafael Holdings' continued to execute on our strategic vision in the fourth quarter, selling our Piscataway property and further increasing our majority stake in LipoMedix. In August, Rafael Pharma announced a major milestone – fully enrolling its pivotal Phase 3 Avenger 500 study for patients with metastatic pancreatic cancer. Results could be available as early as the second quarter of 2021. The Barer Institute has multiple compounds under development and collaboration programs in process with some of the premier academic centers in the country.'

Login
Username:

Password: